Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
Share
Why It Matters
Freenome created a blood test that can screen for two cancers at once. This shows the company is building tools that doctors might want to use.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.